APLIF News and Press, Appili Therapeutics Inc From 09/29/21

AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics - Strategic alliance will accelerate global development of broad spectrum antiviral oral medicine Avigan®/Reeqonus™ (favipiravir) for the treatment of COVID-19 and other infecti...

Strategic alliance for the global development of oral antiviral medicine Avigan®/Reeqonus TM (favipiravir) for the treatment of COVID-19 and other infectious disease programs New agreement with existing consortium partner AiPharma enhances complementary skills and cre...

More than 1,200 patients enrolled in the United States, Mexico, and Brazil Study expected to include patients with top priority COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appil...

New Funds Will Help Expedite Completion of Recently Expanded Pivotal Phase 3 Study on Oral Antiviral Medicine Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development f...

Viral shedding sub-study to assess efficacy against recent COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious di...

Capital Markets Veteran Josef Vejvoda to Join Appili Board of Directors as New Director Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases...

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2022, which en...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the fiscal year ended March 31, 2021, and ...

Appili Therapeutics (APLIF) announces that it has added several clinical research sites in Mexico and Brazil to its Phase 3 clinical trial evaluating Avigan/Reeqonus (favipiravir) as a potential oral therapy for patients with mild-to-moderate COVID-19.The company said that...

Appili Also Provides Additional Trial Updates Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, has added several clinical research sit...